{"id":"W2916451481","doi":"10.1200/jco.18.01042","title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre; Cegep de Saint Jerome","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; Eisai; Pfizer; Moderna; Incyte; Agios Pharmaceuticals; Syndax Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; University of Pennsylvania; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Cancer; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001945999,0.0002561665,0.001626157,0.0001895705,0.00004817901,0.00002240369,0.0001903938,0.0003395333,0.0002181334],"category_scores_gemma":[0.0005544803,0.0001892435,0.0004100958,0.0002148402,0.0002140663,0.0001494151,0.0000567187,0.0007464845,0.000009714373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005188244,"about_ca_system_score_gemma":0.002290636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004957749,"about_ca_topic_score_gemma":0.000364741,"domain_scores_codex":[0.996417,0.0001658135,0.002277111,0.0003477831,0.000394304,0.0003979339],"domain_scores_gemma":[0.9963527,0.001343276,0.001508445,0.0001896539,0.0002750885,0.0003307871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05829777,0.001617744,0.8195168,0.0004007319,0.001626788,0.0007272246,0.000553528,0.0001850698,0.005527543,0.000007683411,0.002266562,0.1092726],"study_design_scores_gemma":[0.1852487,0.02076538,0.7137217,0.001196005,0.0009270016,0.0007462597,0.0009973526,0.005190222,0.001801497,0.0001768286,0.06857041,0.0006586697],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824386,0.004496241,0.00003755194,0.01040144,0.001132882,0.0008765835,0.00001357414,0.00001305894,0.0005900281],"genre_scores_gemma":[0.9909428,0.002736421,0.0017908,0.002672494,0.000277394,0.00003587153,0.00001016076,0.0000355635,0.00149853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1269509,"threshold_uncertainty_score":0.7717125,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03760860318418664,"score_gpt":0.4112338146753233,"score_spread":0.3736252114911366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}